Journal of Clinical Endocrinology & Metabolism, Vol 70, 23-27, Copyright © 1990 by Endocrine Society

ARTICLES

An enzyme linked immunoassay for anti-mullerian hormone: a new tool for the evaluation of testicular function in infants and children

N Josso, L Legeai, MG Forest, JL Chaussain and R Brauner
Unite de Recherches sur l'Endocrinologie du Developpement, INSERM, Hopital des Enfants-Malades, Paris, France.

Anti-Mullerian hormone (AMH), also called Mullerian-inhibiting substance or factor was measured by an interspecific enzyme-linked immunoassay in the serum of 218 normal children and adults of both sexes and in 110 boys with various developmental disorders. AMH levels were high [81.67 ng/ml +/- 7.44(SEM)] in normal males under 2 yr of age, fell progressively in older boys and, decreased sharply at puberty. Serum AMH was not detectable in adults or in females at any age, with very rare exceptions. AMH serum concentrations were significantly decreased in infants with disorders of sex differentiation, particularly testicular dysgenesis, and increased in patients with delayed puberty. In contrast, levels were not significantly affected by either cryptorchidism or chorionic gonadotropin stimulation. AMH shows promise as a marker of testicular function in infancy.

This article has been cited by other articles:

				A.A. Sinisi, D. Esposito, L. Maione, M.C. Quinto, D. Visconti, A. De Bellis, A. Bellastella, G. Conzo, and G. Bellastella Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism Hum. Reprod., May 1, 2008; 23(5): 1029 - 1034. [Abstract] [Full Text] [PDF]

				A. L. Marca and A. Volpe The Anti-Mullerian hormone and ovarian cancer Hum. Reprod. Update, May 1, 2007; 13(3): 265 - 273. [Abstract] [Full Text] [PDF]

				R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo Clin. Cancer Res., March 1, 2006; 12(5): 1593 - 1598. [Abstract] [Full Text] [PDF]

				A. La Marca, S. Giulini, R. Orvieto, V. De Leo, and A. Volpe Anti-Mullerian hormone concentrations in maternal serum during pregnancy Hum. Reprod., June 1, 2005; 20(6): 1569 - 1572. [Abstract] [Full Text] [PDF]

				A. La Marca, S. Malmusi, S. Giulini, L. F. Tamaro, R. Orvieto, P. Levratti, and A. Volpe Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation Hum. Reprod., December 1, 2004; 19(12): 2738 - 2741. [Abstract] [Full Text] [PDF]

				M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee The Role of Mullerian Inhibiting Substance in the Evaluation of Phenotypic Female Patients with Mild Degrees of Virilization J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 787 - 792. [Abstract] [Full Text] [PDF]

				M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee Measurement of Mullerian Inhibiting Substance Facilitates Management of Boys with Microphallus and Cryptorchidism J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3598 - 3602. [Abstract] [Full Text] [PDF]

				M. Fujisawa, T. Yamasaki, H. Okada, and S. Kamidono The significance of anti-Mullerian hormone concentration in seminal plasma for spermatogenesis Hum. Reprod., April 1, 2002; 17(4): 968 - 970. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran, J. Teixeira, A. F. Fuller Jr., P. C. Shah, D. J. Kehas, M. K. Kenneally, D. M. Dombkowski, T. U. Ha, et al. Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS Clin. Cancer Res., November 1, 1999; 5(11): 3488 - 3499. [Abstract] [Full Text] [PDF]

				E. Rajpert-De Meyts, N. Jorgensen, N. Gram, J. Muller, R. L. Cate, and N. E. Skakkebak Expression of Anti-Mullerian Hormone during Normal and Pathological Gonadal Development: Association with Differentiation of Sertoli and Granulosa Cells J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3836 - 3844. [Abstract] [Full Text] [PDF]

				J. Young, R. Rey, B. Couzinet, P. Chanson, N. Josso, and G. Schaison Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2696 - 2699. [Abstract] [Full Text]

				P. Fenichel, R. Rey, S. Poggioli, M. Donzeau, D. Chevallier, and G. Pointis Anti-Mullerian hormone as a seminal marker for spermatogenesis in non-obstructive azoospermia Hum. Reprod., August 1, 1999; 14(8): 2020 - 2024. [Abstract] [Full Text] [PDF]

				R. A. Rey, C. Belville, C. Nihoul-Fékété, L. Michel-Calemard, M. G. Forest, N. Lahlou, F. Jaubert, I. Mowszowicz, M. David, N. Saka, et al. Evaluation of Gonadal Function in 107 Intersex Patients by Means of Serum Antimullerian Hormone Measurement J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 627 - 631. [Abstract] [Full Text]

				M. M. Lee, P. K. Donahoe, B. L. Silverman, T. Hasegawa, Y. Hasegawa, M. L. Gustafson, Y. Chang, and D. T. MacLaughlin Measurements of Serum Mullerian Inhibiting Substance in the Evaluation of Children with Nonpalpable Gonads N. Engl. J. Med., May 22, 1997; 336(21): 1480 - 1486. [Abstract] [Full Text] [PDF]